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ABSTRACT
Given the rich blood supply to the prostate and the adjacent
Santorini’s plexus, radical prostatectomy is associated with
significant blood loss even in patients with normal coagula-
tion profiles. In patients with hemophilia, any surgical pro-
cedure carries a risk of significant hemorrhage due to a
deficiency of factors in the coagulation cascade. For these
reasons, hemophiliac patients have often been encouraged
to undergo radiation or other forms of nonsurgical treatment
for clinically localized prostate cancer. However, the de-
creased blood loss associated with a laparoscopic/robotic
approach and appropriate perioperative factor transfusions
can minimize the risk of hemorrhage during robotic-assisted
radical prostatectomy. We present the case report of a suc-
cessful robotic-assisted laparoscopic prostatectomy in a pa-
tient with mild hemophilia A, with an estimated blood loss
for the procedure of 20mL. We will focus on the periopera-
tive management of the patient’s factor replacement.
Key Words: Prostatic neoplasm, Prostatectomy, Hemo-
philia A, Robotic.
INTRODUCTION
Better hematological management has reduced bleed-
ing complications in patients with acquired or congen-
ital bleeding disorders who have undergone surgery.
Successful open subtotal and transurethral prostatec-
tomy has previously been described in patients with
known hemorrhagic disorders after appropriate periop-
erative preparation.1 One case report of a successful
extraperitoneal laparoscopic radical prostatectomy has
been described in a patient with hemophilia B (factor
IX deficiency).2 We present the first report to date of a
successful transperitoneal robotic-assisted laparoscopic
prostatectomy (RALP) in a patient with hemophilia A
(factor VIII deficiency).
CASE REPORT
The patient was a 69-year-old white male with mild he-
mophilia A, who was diagnosed with clinically localized
prostate cancer following evaluation for an abnormal dig-
ital rectal examination (T2a nodule). His PSA was 1.3. He
underwent a prostate biopsy with periprocedural intrana-
sal 1-deamino 8-D arginine vasopressin (dDAVP) and oral
aminocaproic acid without bleeding complications, which
revealed Gleason 34 7 prostate cancer in 15% of one
core. Prostate volume on ultrasound was 30mL. Aside
from the hemophilia, the patient’s past medical history is
significant for lower urinary tract symptoms managed with
alpha-blockers and morbid obesity, with a body mass
index of 38. He had a prior surgical history of a left hip
replacement in 1998, which was managed without bleed-
ing complications following factor VIII replacement. All
treatment options were discussed, the patient sought nu-
merous opinions from urologists and radiation oncolo-
gists, and the patient opted for RALP.
Surgical Management
The patient underwent successful RALP with bilateral pel-
vic lymphadenectomy and bilateral nerve sparing with no
bleeding complications and an estimated blood loss of
20mL. No hemostatic agents, such as Surgicel (Ethicon,
Somerville, NJ) or Floseal (Baxter, Deerfield IL), were
used during the procedure. He remained hospitalized
Department of Urology, The Mount Sinai Medical Center, New York, New York
USA (all authors).
Department of Anesthesiology, The Mount Sinai Medical Center, New York, New
York USA (Dr Gainsburg).
Address correspondence to: David B. Samadi, MD, 625 Madison Avenue, Suite 230,
New York, NY 10022, USA. Telephone: (212) 241–8766, Fax: (212) 308–6107,
E-mail: david.samadi@mountsinai.org
DOI: 10.4293/108680810X12924466007287
© 2010 by JSLS, Journal of the Society of Laparoendoscopic Surgeons. Published by
the Society of Laparoendoscopic Surgeons, Inc.
JSLS (2010)14:439–441 439
CASE REPORTuntil postoperative day (POD) 4 for careful hematologic
monitoring and product administration. A small hema-
toma was noted at his Jackson-Pratt drain site on POD 4,
but he was hemodynamically stable and asymptomatic.
The Foley catheter was removed on POD 10. Final histo-
pathology was pT2cN0, Gleason 347 with negative
surgical margins and 10 negative lymph nodes.
He had very mild hematuria intermittently following cath-
eter removal, but voided well until POD 28, when he
developed gross hematuria and clot urinary retention.
Following a failed attempt at Foley catheter placement, he
was admitted. Cystourethroscopy was performed that re-
vealed a small clot at the widely patent bladder neck and
a slowly bleeding area at the level of the urethrovesical
anastomosis. This area was fulgurated, no further bleeding
was identified, and a Foley catheter was placed. No fur-
ther hematuria was noted, and he passed a trial of void 3
days later. Since then, no further complications have de-
veloped, and his PSA is undetectable.
Hematologic Management
Baseline factor VIII levels were 8% to 14% (normal range,
50% to 150%), with a response of 50% with dDAVP. This
is consistent with mild hemophilia A. The goal was to
keep his factor VIII levels above 100% during surgery and
above 30% for 14 days postoperatively. On the morning of
surgery, he received 20ug of intravenous dDAVP and 2720
IU of intravenous concentrated factor VIII with von Wil-
lebrand factor (Alphanate). His postoperative factor VIII
level was 87%, and his hemoglobin was 13.9g/dL. Post-
operatively, he received 2720IU of Alphanate every 12
hours for 3 days; in the 24 hours prior to discharge, he
received 2 doses of 4080 IU. He also received 20ug of
intravenous dDAVP daily for the first 2 postoperative days.
Hemoglobin on POD one was 13.2; it reached a nadir of
13.0 on POD 3. His factor VIII level remained between
84% and 120% throughout his hospital course and peaked
at 190% immediately prior to discharge.
Following discharge, he received infusions of 4080 IU of
Alphanate daily for 7 days, then 2720 IU daily for another
7 days. An outpatient factor VIII level was drawn on POD
7, which at 66% was within the target range. At the time of
readmission for gross hematuria on POD 28, his factor VIII
level had dropped to 24% but his hemoglobin was 15.0.
Prior to his cystourethroscopy, he received intranasal
dDAVP. He then received 4080 IU every 12 hours for 2
doses, and his factor VIII level responded to 74%.
DISCUSSION
Open radical retropubic prostatectomy carries a high risk
of intraoperative blood loss due to its rich blood supply
and anatomic location deep in the pelvis and adjacent to
Santorini’s plexus. However, the tamponade provided by
pneumoperitoneum and better visualization of vascular
structures offered by the laparoscopic approach has sub-
stantially decreased the average blood loss during robotic
radical prostatectomy.3,4 The widespread availability and
appropriate use of coagulant factors has also improved
the perioperative management of hemophiliac patients
undergoing surgery.5 However, persistent concern regard-
ing intraoperative hemorrhage has led many urologists to
consider radiation or other forms of primary prostate can-
cer treatment in patients with hemophilia.
Our patient was extremely well informed about prostate
cancer and its various treatment options. He had no in-
terest in active surveillance. He sought opinions from
several open surgeons who felt that his risk of intraoper-
ative hemorrhage was too great to undergo open radical
retropubic prostatectomy, and recommended radiation
therapy. Radiation oncologists felt that he was an appro-
priate candidate for intensity modulated radiation therapy.
However, the patient was concerned that his bothersome
preoperative voiding symptoms would worsen following
radiation therapy. He was most interested in undergoing
radical prostatectomy. A lengthy discussion was held with
him regarding the risks and benefits of surgery, including
the need for factor administration and longer postopera-
tive monitoring than usual, and he was accepting of the
risks. Considering that he had previously undergone suc-
cessful orthopedic surgery without bleeding complica-
tions, he was confident that he could avoid significant
morbidity following prostatectomy.
A multidisciplinary approach involving the urology, he-
matology, and anesthesia teams was used to coordinate
his care. As there had been no reported experience with
the management of hemophilia A in this situation, the
hematologic decisions were empiric, based on experience
with orthopedic and other open surgeries. It is recom-
mended that patients undergoing surgery have factor VIII
levels between 80% to 100% at the time of surgery and be
maintained above 30% for at least 10 days to 14 days after
surgery.5,6
Patients with mild hemophilia A synthesize functional
factor VIII, but at levels too low to be therapeutic. Such
patients respond to dDAVP, which releases factor VIII and
von Willebrand factor (vWF) from platelets, increasing
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patients with severe hemophilia do not produce any func-
tional factor VIII, and thus do not respond to dDAVP. In
addition to dDAVP, purified factor VIII is available for
intravenous infusion. This is usually necessary to achieve
the factor VIII levels required in the perioperative period.
Alternatively, cryoprecipitate can be utilized; however, it
can require as much as 15 units to 20 units for effective
replacement.6
One risk of factor replacement, however, is the develop-
ment of antibodies to factor VIII, known as inhibitors,
which functionally inhibit it. After the patient develops
such inhibitors, it is much more difficult to control future
bleeding episodes, as transfused factor VIII is less effec-
tive. The use of vWF in addition to concentrated human
factor VIII has been reported to reduce the risk of inhibitor
development, which was the rationale for using Alphanate
in our patient.7
His postoperative factor replacement regimen remains a
topic of debate. During his postoperative prophylactic
Alphanate replacement, he did not have any bleeding
issues. Potentially, this was overcautious and unnecessary;
perhaps he could have been managed with purified factor
VIII alone or simply intranasal dDAVP. Clearly, when he
had a bleeding complication on POD 28, his factor VIII
level was subtherapeutic. It is unknown whether this
complication could have been prevented by maintaining
his factor VIII level above 30% at that time.
Kernoff8 reported several cases of suprapubic or transure-
thral prostatectomies in which there were extensive blood
loss and massive blood requirements. Following the de-
velopment and availability of factor concentrates, similar
procedures had improved rates of intraoperative hemor-
rhage and the postoperative course.9,10 Goldsmith1 later
described a successful perioperative management plan in
hemophiliac patients who underwent subtotal prostatec-
tomy. However, given the effective medical treatments for
benign prostatic hyperplasia that were subsequently de-
veloped, the need for surgical intervention in such pa-
tients largely disappeared. With the growing acceptance
of laparoscopic radical prostatectomy, this procedure is
now feasible in patients with hemophilia.2
This case demonstrates that with a multidisciplinary ap-
proach, RALP can successfully be performed in patients
with hemophilia A. The patient was observed in the hos-
pital for 3 days longer than the standard one night stay,
and there was a Clavien grade III bleeding complication at
POD 28 that required surgical intervention.11 It is possible
that this could have been avoided by longer home use of
intranasal dDAVP or intravenous factor VIII. We will use
this information as we work toward establishing a proto-
col for the postoperative management of persons with
hemophilia undergoing RALP.
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